Compare Cassava Sciences Inc (FLNA) vs Southern Copper Corp (SCCO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cassava Sciences Inc vs Southern Copper Corp — how do they compare? Cassava Sciences Inc trades at $0.83 (market cap $39.40M), while Southern Copper Corp trades at $204 (market cap $167.74B). The key difference: Southern Copper Corp is far larger — about 4257.4× Cassava Sciences Inc's market cap, and Southern Copper Corp pays a 2.21% dividend while Cassava Sciences Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Cassava Sciences Inc for 37 Days and Southern Copper Corp for 61 Days on average.
| FLNA | SCCO | |
|---|---|---|
Market Cap | $39.40M | $167.74B |
Volume | 759,018 | 853,110 |
Sector | Health | Basic Materials |
52-Week High | $4.64 | $219.70 |
52-Week Low | $0.68 | $120.02 |
Typical Hold Time | 37 Days | 61 Days |
Enterprise Value | -$43.28M | $169.03B |
Dividend Yield | — | 2.21% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Filana Therapeutics (FLNA) trades at $0.82, down 6.77% today, amid bearish technical signals but with positive fundamental catalysts. The company shows improving quarterly EPS beats and a favorable EV/EBITDA of 1.03, though it remains unprofitable with negative cash flow. Recent FDA clearance for its epilepsy drug trial has generated optimism, reflected in strong analyst buy ratings (67% consensus).
The outlook balances clinical progress against financial strain. The FDA hold lift on simufilam provides a clear near-term catalyst for Phase 2a trials starting in 2027, supporting the bullish analyst view. However, high cash burn (-$33M net CF in 2025) and lack of revenue pose significant risks to sustainability, requiring careful monitoring of funding and trial milestones.
SCCO trades at $200.57, down 1.81% on the day, with technical indicators showing neutral momentum. The company demonstrates strong fundamentals with revenue growth from $13.42B in 2025 to projected $15.8B in 2026 and impressive profitability margins including 35.87% net income margin. Recent earnings beats and a $10.2B Mexican project pipeline support growth prospects, though the stock trades at premium valuations with P/E of 30.1 and P/S of 10.82.
While SCCO's operational strength and copper demand from AI infrastructure provide upside potential, the stock faces headwinds from its premium valuation relative to peers and mixed analyst sentiment with only 10.34% buy ratings. The current price sits above the consensus target of $167.67, suggesting limited near-term upside despite strong cash flow generation and dividend payments.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Cassava Sciences Inc
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →About Southern Copper Corp
Southern Copper Corp is an integrated producer of copper and other minerals and operates the mining, smelting, and refining facilities in Peru and Mexico. Its production includes copper, molybdenum, zinc, and silver. The company operates through the following segments: Peruvian operations, Mexican open-pit operations, and Mexican underground mining operations. Southern Copper generates the majority of its revenue from the sale of copper and the rest from the sale of non-copper products, such as molybdenum, silver, zinc, lead, and gold. Its geographical segments are The Americas, Europe, and Asia.
Read more on SCCO →
